NVONovo Nordisk A/S
What is the market doing?
No clear lean: nothing decisive, though in a downtrend (−14% vs 200-day).
In a downtrend, below its 50- and 200-day averages. Price is −14% vs its 200-day average.
A token position, settled Sep 15, 2026, a few days of normal trading to cover. Down 17% since the previous count, unchanged over three months.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How NVO is trading
Novo Nordisk A/S is −35% over the past year while the S&P 500 is +18%: 53 points behind the market.
1-year return · S&P 500 +18%
- vs 200-day average
- −14%
vs 200-day average · a clear downtrend
- RSI (14)
- 39
RSI (14) · neutral
- Below its 52-week high
- 37%
Below its 52-week high
Details›
- Last close2026-10-09
- $38.62
- 1 monthS&P 500 +2.7%
- −12%
- 1 yearS&P 500 +18%
- −35%
- 5 yearsS&P 500 +88%
- −15%
- vs 50-day average$43.58
- −11%
- 52-week high
- $61.72
- 52-week low
- $34.76
- Annualised volatility
- 48%
| Year | Return |
|---|---|
| 2026 (year to date) | −21% |
| 2025 | −39% |
| 2024 | −16% |
| 2023 | +55% |
| 2022 | +23% |
| 2021 | +64% |
| 2020 | +23% |
| 2019 | +29% |
| 2018 | −12% |
| 2017 | +54% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 10 | 7 of 10 | +2.9% |
| Feb | 10 | 6 of 10 | −2.8% |
| Mar | 10 | 6 of 10 | +1.6% |
| Apr | 10 | 6 of 10 | +3.5% |
| May | 10 | 7 of 10 | +3.2% |
| Jun | 10 | 7 of 10 | +2.0% |
| Jul | 11 | 5 of 11 | −1.0% |
| Aug | 11 | 7 of 11 | +3.6% |
| Sep | 11 | 2 of 11 | −4.9% |
| Oct | 11 | 6 of 11 | −0.50% |
| Nov | 10 | 6 of 10 | +2.5% |
| Dec | 10 | 8 of 10 | +1.5% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Drug Manufacturers, General
Ranks #1 of 7 by RyuScore